A Poisson approach to the validation of failure time surrogate endpoints in individual patient data meta-analyses
- PMID: 28681681
- DOI: 10.1177/0962280217718582
A Poisson approach to the validation of failure time surrogate endpoints in individual patient data meta-analyses
Abstract
Surrogate endpoints are often used in clinical trials instead of well-established hard endpoints for practical convenience. The meta-analytic approach relies on two measures of surrogacy: one at the individual level and one at the trial level. In the survival data setting, a two-step model based on copulas is commonly used. We present a new approach which employs a bivariate survival model with an individual random effect shared between the two endpoints and correlated treatment-by-trial interactions. We fit this model using auxiliary mixed Poisson models. We study via simulations the operating characteristics of this mixed Poisson approach as compared to the two-step copula approach. We illustrate the application of the methods on two individual patient data meta-analyses in gastric cancer, in the advanced setting (4069 patients from 20 randomized trials) and in the adjuvant setting (3288 patients from 14 randomized trials).
Keywords: Surrogate endpoint; copula; failure time; meta-analysis; randomized trials.
Similar articles
-
surrosurv: An R package for the evaluation of failure time surrogate endpoints in individual patient data meta-analyses of randomized clinical trials.Comput Methods Programs Biomed. 2018 Mar;155:189-198. doi: 10.1016/j.cmpb.2017.12.005. Epub 2017 Dec 13. Comput Methods Programs Biomed. 2018. PMID: 29512498 Review.
-
One-step validation method for surrogate endpoints using data from multiple randomized cancer clinical trials with failure-time endpoints.Stat Med. 2019 Jul 20;38(16):2928-2942. doi: 10.1002/sim.8162. Epub 2019 Apr 17. Stat Med. 2019. PMID: 30997685
-
A joint frailty-copula model for meta-analytic validation of failure time surrogate endpoints in clinical trials.Biom J. 2021 Feb;63(2):423-446. doi: 10.1002/bimj.201900306. Epub 2020 Oct 1. Biom J. 2021. PMID: 33006170
-
Validation of surrogate endpoints in cancer clinical trials via principal stratification with an application to a prostate cancer trial.Stat Med. 2017 Aug 30;36(19):2963-2977. doi: 10.1002/sim.7318. Epub 2017 May 8. Stat Med. 2017. PMID: 28485043
-
Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials.Cancer J. 2009 Sep-Oct;15(5):421-5. doi: 10.1097/PPO.0b013e3181b9c602. Cancer J. 2009. PMID: 19826362 Review.
Cited by
-
Dynamic Risk Prediction via a Joint Frailty-Copula Model and IPD Meta-Analysis: Building Web Applications.Entropy (Basel). 2022 Apr 22;24(5):589. doi: 10.3390/e24050589. Entropy (Basel). 2022. PMID: 35626474 Free PMC article.
-
Surrogate Clinical End Points in Studies of APOL1-Associated Kidney Disease: Just in Time.Clin J Am Soc Nephrol. 2025 Jan 1;20(1):3-5. doi: 10.2215/CJN.0000000628. Epub 2024 Dec 16. Clin J Am Soc Nephrol. 2025. PMID: 39680444 No abstract available.
-
An alternative trial-level measure for evaluating failure-time surrogate endpoints based on prediction error.Contemp Clin Trials Commun. 2019 Jul 5;15:100402. doi: 10.1016/j.conctc.2019.100402. eCollection 2019 Sep. Contemp Clin Trials Commun. 2019. PMID: 31338479 Free PMC article.
-
How to use frailtypack for validating failure-time surrogate endpoints using individual patient data from meta-analyses of randomized controlled trials.PLoS One. 2020 Jan 28;15(1):e0228098. doi: 10.1371/journal.pone.0228098. eCollection 2020. PLoS One. 2020. PMID: 31990928 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources